» Articles » PMID: 29208429

Checkpoint Inhibitors and Aspergillosis in AML: the Double Hit Hypothesis

Overview
Journal Lancet Oncol
Specialty Oncology
Date 2017 Dec 7
PMID 29208429
Citations 13
Authors
Affiliations
Soon will be listed here.
Citing Articles

The Impact of Dimitrios P. Kontoyiannis on Mucormycosis Research.

Lewis R J Fungi (Basel). 2024; 10(6).

PMID: 38921367 PMC: 11205125. DOI: 10.3390/jof10060382.


Circulatory Inflammatory Proteins as Early Diagnostic Biomarkers for Invasive Aspergillosis in Patients with Hematologic Malignancies-an Exploratory Study.

Aerts R, Ricano-Ponce I, Bruno M, Mercier T, Rosati D, Maertens J Mycopathologia. 2024; 189(2):24.

PMID: 38407673 PMC: 10896822. DOI: 10.1007/s11046-024-00831-8.


Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions.

Wurster S, Watowich S, Kontoyiannis D Front Immunol. 2022; 13:1018202.

PMID: 36389687 PMC: 9640966. DOI: 10.3389/fimmu.2022.1018202.


Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis.

Wurster S, Albert N, Bharadwaj U, Kasembeli M, Tarrand J, Daver N Front Immunol. 2022; 13:838344.

PMID: 35251033 PMC: 8896628. DOI: 10.3389/fimmu.2022.838344.


Aspergillus fumigatus and Aspergillosis in 2019.

Latge J, Chamilos G Clin Microbiol Rev. 2019; 33(1).

PMID: 31722890 PMC: 6860006. DOI: 10.1128/CMR.00140-18.